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Hemorrhagic cystitis (HC) occurring after allogeneic transplantation signiﬁcantly affects quality of life and, in
some cases, becomes intractable, increasing the risk of death. To date, its therapy is not established. We used
the hemostatic agent ﬁbrin glue (FG) to treat 35 patients with refractory post-transplantation HC. Of 322
adult patients undergoing an allogeneic transplantation for hematological malignancy, 35 developed grade 
2 HC refractory to conventional therapy and were treated with FG, diffusely sprayed on bleeding mucosa by
an endoscopic applicator. The cumulative incidence of pain discontinuation and complete remission, deﬁned
as regression of all symptoms and absence of hematuria, was 100% at 7 days and 83%  7%, respectively, at
50 days from FG application. The 6-month probability of overall survival for all 35 patients and for the 29 in
complete remission was 49%  8% and 59%  9%, respectively. In the matched-pair analysis, the 5-year
probability of overall survival for the 35 patients with HC and treated with FG was not statistically
different from that of the comparative cohort of 35 patients who did not develop HC (32%  9% versus
37%  11%, P ¼ not signiﬁcant). FG therapy is a feasible, effective, repeatable, and affordable procedure for
treating grade 2 HC after allogeneic transplantation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hemorrhagic cystitis (HC) is a major complication of
allogeneic hematopoietic stem cell transplantation (HSCT),
characterized by the presence of continuous macroscopic
hematuria occurring in absence of gynecologic and urologic
disease or bacterial and fungal infections of the urinary tract
[1-5]. With symptoms ranging from hematuria to renal fail-
ure, HC signiﬁcantly affects the quality of life, prolongs hos-
pitalization, increases the cost of allogeneic HSCT [6], and, in
some cases, can become an intractable and life-threateningedgments on page 1616.
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14.06.018disease [1-4]. Indeed, HC is correlated with an increased
risk of transplantation mortality [7] and reduced probability
of survival [8].
Discrepancies in deﬁning the diagnostic criteria are
partially responsible for the variability of HC incidence,
which ranges from 7% to 68% in the setting of allogeneic
HSCT [9,10]. HC occurring more than 10 days after trans-
plantation is deﬁned as late clinical form, ranges from 12% to
25%, and usually lasts from weeks to months [11]. A number
of variables have been identiﬁed as signiﬁcant risk factors for
developing HC, including allogeneic HSCT, intensity of the
conditioning regimen, alternative donor of hematopoietic
stem cells (HSC) (haploidentical, matched unrelated donor,
umbilical cord blood), and advanced grade of acute graft-
versus-host disease (GVHD) [1-5,7]. Finally, reactivation of
polyoma BK virus (BKV), adenovirus, and cytomegalovirus
have been signiﬁcantly correlated with higher incidence ofTransplantation.
Figure 1. Epidemiology of hemorrhagic cystitis (Rome Transplant Network,
January 2006 to December 2012).
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between BKV reactivation and occurrence of late-onset HC
remains an issue of discussion [12-14]. HC refractory to
conventional therapies (hyperhydration, bladder irrigation,
antiviral drugs, and transfusion support) is extremely difﬁ-
cult to manage and, to date, neither intravesical nor systemic
therapy have been established [5,7,15-30]. Favorable results
have been reported in some cases, but the experiences are
limited and related to the expertise of a single trans-
plantation center. Furthermore, most of these therapies are
very expensive and sometimes complicated by relevant side
effects, such as bladder ﬁbrosis, urinary incontinence, or
renal or nervous toxicity. Invasive and particularly aggressive
approaches, such as fulguration, vesical artery embolism,
nephrotomy, uretheral resection, and partial or total cys-
tectomy have been variably proposed as ultimate therapeutic
options in extremely debilitated patients with intractable
and life-threatening forms of HC [31].
We report the results of treatment of grade 2 to 4 HC by
using the human plasma-derived hemostatic agent ﬁbrin
glue (FG) through endoscopic application on bladder mucosa
in adult patients submitted to allogeneic HSCT.PATIENTS AND METHODS
HC Grading
HC was classiﬁed according to standard published criteria into 4 grades:
microscopic hematuria (grade 1), macroscopic hematuria (grade 2), hema-
turia with clots requiring transfusion support (grade 3), and macroscopic
hematuria with clots and impaired renal function (grade 4) [2,3].Table 1
Clinical Characteristics of Patients Treated with Fibrin Glue
Characteristic n (%)
Patients 35Patient Selection Criteria
All patients with HC were ﬁrst treated with conventional therapy con-
sisting of hyperhydration, continuous bladder irrigation, transfusion sup-
port with platelet concentrates, and, limited to 15 patients, cidofovir.
Patients selected for FG treatment met the following criteria: (1) progression
from grade 1 to grade 2 HC on conventional therapy, and (2) grade  2 HC
not responding to conventional therapy.Age, median (range), yr 35 (18-54)
Male 15 (43)
Malignant disease
Lymphoid 20 (60)
Myeloid 15 (40)
Type of allogeneic HSCT
HLA-identical sibling 6 (18)
Matched unrelated donor 8 (24)
Umbilical cord blood 4 (12)
Haploidentical donor 17 (46)
Conditioning regimen
Myeloablative TBF 29 (83)
Reduced-intensity TBF 2 (6)
Including CTX 4 (11)
Engraftment, median (range), d 18 (12-46)
Acute GVHD  II grade 12 (34)
Onset of grade  2 HC, median (range), d 34 (8-146)
BK-positive viruria
At time of HSCT 15 (44)
At time of HC onset 35 (100)
BK-positive viremia
At time of HSCT (evaluable, n ¼ 13) 3 (23)
At time of HC onset (evaluable, n ¼ 12) 7 (58)
HC gradePatients
Between January 2006 and December 2012, 1137 patients (children,
n ¼ 246; adults, n ¼ 891) underwent HSCT for malignant and nonmalignant
diseases and were registered at the Rome Transplant Network, a Joint
Accreditation Committee ISCT EBMT (JACIE)-accredited metropolitan
transplantation program established in Rome and including 7 trans-
plantation centers. Of 891 adult patients, 569 (64%) underwent autologous
and 322 (36%) underwent allogeneic HSCT. No recipients of autologous HSCT
experienced HC, which occurred in 76 (24%) patients submitted to alloge-
neic HSCT and was of grade  2 in 45 (14%). For the 322 allogeneic trans-
plantations, the HSC source was HLA-identical sibling in 146, matched
unrelated donor in 72, umbilical cord blood in 30, and haploidentical family
donor in 74, with an incidence of grade 2 HC of 6%, 14%, 17%, and 28%,
respectively. Of the 45 patients with grade2 HC, 35 (78%) with median age
of 35 years (range, 18 to 54) underwent endoscopic FG therapy, which was
not feasible for the other 10 patients because of very severe clinical condi-
tions with or without disease progression (Figure 1). The study was
approved by the institutional review board of each participating institution.
Informed consent for the treatment was obtained from all patients in
accordance with the Declaration of Helsinki.
Patient and clinical characteristics of the 35 patients with grade  2 HC
are summarized in Table 1.Grade II 11 (31)
Grade III 21 (60)
Grade IV 3 (9)
Peripheral blood counts at time of HC onset,
median (range)
Hb, g/dL 8.8 (6.9-13)
Neutrophils,  103/mL 4.5 (.1-23.6)
Platelets,  103/mL 30 (4-170)
TBF indicates thiotepa, busulfan, and ﬂudarabine; CTX, cyclophosphamide;
Hb, hemoglobin.
Data presented are n (%) unless otherwise indicated.Preventive Measures
Antithymocyte globulinwas included in the conditioning regimen for all
patients who underwent transplantation from an alternative donor. As anti-
infective prophylaxis, all patients treated in high-efﬁciency particulate-
ﬁltered air rooms with positive pressure received ciproﬂoxacin combined
with ﬂuconazole and acyclovir. Hyperhydration, forced diuresis, and
urine alkalinization were given to all patients during the conditioning
regimen. As preventive measures for drug-related chemical cystitis, mer-
captoethane sodium sulfonate was administered to patients receiving
cyclophosphamide.Engraftment and GVHD Deﬁnition
Engraftment was deﬁned as the ﬁrst of 3 consecutive days of
.5  106/mL polymorphonuclear cells in the peripheral blood. GVHD was
graded according to the standard criteria [32]. All patients engrafted at a
median of 18 days (range, 12 to 46) and 12 of them (34%) developed 2
grade acute GVHD.BKV Monitoring and Antiviral Therapy
BKV replication in both urine and plasma was determined by poly-
merase chain reaction.
BK viruria was tested for all patients before transplantation and then
once each week until 100 days after HSCT. A positive result was considered
signiﬁcant for values > 9  106 copies/mL.
Antiviral therapy with i.v. cidofovir at a dose of 5 mg/kg associated with
probenecid was given weekly over 21 days to the ﬁrst 15 patients with BK-
Figure 2. Flow chart of treatment and response.
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i.v. cidofovir therapy was not further administered after the occurrence of
severe nephrotoxicity in 2 patients.
Fibrin Glue Treatment: Production and Application Technique
Details on all technical aspects of FG treatment have been previously
reported [33].
FG Production
FG was obtained from virus-inactivated fresh frozen human plasma
(Octaplas, Vienna, Austria) and produced using Vivostat System (Vivolution,
Birkeroed, Denmark), an automatic method for processing and applying FG
starting from either whole blood or fresh frozen plasma. The entire process
generates approximately 6 mL of sealant from 120 mL of the patient’s own
blood or fresh frozen plasma in about 30 minutes. For each application,
12 mL of FG was prepared. Details of the biochemical process of the Vivostat
System have been reported elsewhere [34]. FG produced by Vivostat System
provides some technical advantages compared with other conventional
devices, such as enhanced instant adhesion, strength, and elasticity because
of fast polymerization; airﬂow rates and spray forces that are lower and less
variable than conventional systems; and more consistent thickness of the
ﬁbrin ﬁlm.
FG Application
To deﬁne type and extension of mucosal lesions and to perform clot
evacuation, patients on sedation and O2 ventilation underwent conventional
cystoscopy. The insertion of FG endoscopic application system required the
use of a 3-mm to 5-mm bore cystoscope. A laparoscopic CO2 insufﬂator
connected to the cystoscope maintained the bladder distension at a constant
pressure of 12 mmHg. The endoscopic FG applicator was inserted trough the
lumen of the cystoscope and the glue was sprayed on the bleeding and raw
surfaces of bladder mucosa. A median of 12 mL FG was used for each appli-
cation. The visual means through the cystoscope and the rotation of the
endoscopic catheter spraying the glue over the damaged areas represent the
main advantages for an appropriate application of the ﬁbrin adhesive in the
bladder. Spraying the glue together with CO2 insufﬂation allows the bladder
to be kept under constant pressure, avoiding overﬂow and overdistension. At
the end of the procedure, a ﬁnal cystoscopy with low CO2 insufﬂation pres-
sure checked the FG adhesion and hemostatic efﬁcacy. In the absence of
active bleeding, a Foley catheter without bladder irrigation was positioned
and removed on the disappearance of hematuria. Before FG therapy, no pa-
tientwith grade2 HC received i.v. tranexamic acid, whichwas administered
only to patients with persistence of mild hematuria after FG application.
Patients with persistent hematuria received more than 1 FG application.
Criteria of Response
The response to FG treatment was deﬁned as 1 of the following:
(1) clinical response, disappearance of dysuria, urgency, and frequency;
analgesic agent discontinuation; and Foley catheter removal with persis-
tence of hematuria; (2) complete response (CR), clinical response and
absence of hematuria; or (3) no response, no clinical response and persis-
tence of hematuria.
Statistical Analysis
A descriptive analysis for the demographic and clinical characteristics of
the patients was performed including median, standard deviations, and
range for continuous variables and absolute and relative frequencies for
categorical variables. Taking into account the corresponding competing
risks, the probabilities of neutrophil engraftment, GVHD, pain discontinu-
ation, catheter removal, complete response, and relapse were estimated
with the cumulative incidence (CI) method [35]. Selection of a random
sample of non-HC patients for matched pair-analysis was carried out with
the SAS “survey select” procedure. Matching was performed for period of
transplantation, patient sex and age, diagnosis (lymphoid or myeloid), dis-
ease status at transplantation (early or advanced), and HSC source (HLA-
identical sibling, haploidentical, matched unrelated donor, or cord blood).
Overall survival curves were estimated according to the Kaplan-Meier
product-limit method [36] and were tested for signiﬁcant differences us-
ing the log-rank test. A 2-tailed value <.05 was considered statistically
signiﬁcant. Multivariate analysis could not be conducted because of lack of
model ﬁt, due to the small sample size. All analyses were conducted using
software SAS 9.3.1 (Statistical Analysis System, Cary, NC) and R version 2.15.0
(http://www.r-project.org).
RESULTS
The median time from transplantation to the HC onset
was 34 days (range, 8 to 146). HC was classiﬁed as grade 2 in11 patients (31%), grade 3 in 21 (60%), and grade 4 in 3 pa-
tients (9%). At the onset of HC, BK viruria was positive in all
patients, whereas BK viremia was positive in 58% of the
evaluable patients (Table 1).
Before FG therapy, standard supportive care for HC con-
sisted of hyperhydration, bladder irrigation, and transfusion
therapy for all patients. Sixteen patients (46%) with BK
viruria 55  106 copies/mL received antiviral therapy with
cidofovir. Transfusion therapy consisted of a median of 4
(range, 1 to 27) red blood cell units in 31 of 35 (89%) patients
and 18 (range, 2 to 60) doses of platelet concentrates in 29 of
35 (83%).
The ﬁrst FG treatment was applied at a median of 52 days
(range,18 to 163) fromHSCTand 12 days (range,1 to 65) from
HC onset. The median volume of FG used was 10.6 mL (range,
6.3 to 15 mL) and the procedure lasted a median time of
45 minutes (range, 35 to 90 minutes). The procedure was
well tolerated by the patients and no side effects were
observed. A ﬂow chart of FG treatment and response is
summarized in Figure 2.
All patients achieved clinical response with a CI of anal-
gesic agent discontinuation of 100% at 7 days with a median
of 24 hours from the procedure (Figure 3A). The CI of Foley
catheter removal was 93%  5% at 30 days with a median of
5 days (Figure 3B).
Overall, of the 35 patients, 6 (17%) did not respond and 29
(83%) entered CR, which was achieved after 1, 2, or 3 FG
applications in 21 (60%), 6 (17%), and 2 (6%) patients,
respectively. According to the HC grade, CR was reached in 9
of 11 (82%) patients with grade II, 19 of 21 (90%) with grade
III, and in only 1 of 3 with grade IV. With a median of 14 days,
the CI of CR was 83%  7% at 50 days (Figure 4A). Although
the difference was not statistically signiﬁcant, the proportion
of patients treated with FG later than 12 days from the HC
onset and achieving CR was lower (76.5%  11%) than that of
patients treated before 12 days (89%  10%) (Figure 4B). Of
the 29 patients who entered CR, 7 relapsed, with a CI of
24%  8% at 100 days; all relapses occurred within 30 days
from CR. BK viremia was tested in only 12 patients, 7 of
whom, a number too low for any evaluation, received cido-
fovir. However, BK viruria remained positive in 83% of the 29
patients achieving CR. Of 16 patients treated with cidofovir,
12 (75%) achieved CR, which was reached by 17 of 19 (89%)
patients not given cidofovir. Considering only patients with
grade 3 HC treated (n ¼ 11) and untreated (n ¼ 10) with
cidofovir, the proportion of patients achieving CR was 91%
Figure 3. Clinical response, deﬁned as analgesic agent discontinuation (A) and Foley catheter removal (B), in the 35 patients with hemorrhagic cystitis. CI indicates
cumulative incidence.
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35 patients and for the 29 in CR was 49%  8% and 54%  9%,
respectively. From the matched-pair analysis, the 5-year
probability OS from transplantation for the 35 patients with
HC and treated with FG was not statistically different from
that of the corresponding cohort of 35 patients who did not
develop HC (32%  9% versus 37%  11%, P ¼ not signiﬁcant)
(Figure 5).
DISCUSSION
The widespread use of donor sources alternative to
HLA-identical siblings, in particular, unmanipulated hap-
loidentical transplantation, is correlated with an increasing
incidence of HC after allogeneic HSCT in recent years [37-39].
In the absence of standardized therapies for treatment of
severe HC, we used endoscopically applied FG, a sealant
largely employed with favorable results in different surgical
settings, including urological procedures [40,41]. In contrast
to synthetic adhesives, ﬁbrin sealants have the advantage of
being biocompatible and biodegradable and they are not
associated with inﬂammation, foreign body reactions, tissue
necrosis, or extensive ﬁbrosis.
Herein, we report results of a clinical study on 35 adult
patients who received allogeneic HSCT from different source,
undergoing the FG intravesical application for treatment of
severe HC. Five of these patients have been previously
described [33]. Before this previous report, only 2 cases withFigure 4. Complete remission in the 35 patients with hemorrhagic cystitis (A) and co
cumulative incidence; ns, not signiﬁcant.refractory HC after HSCT and successfully treated with FG
have been reported [42,43].
All 35 patients presented 2 grade HC refractory to con-
ventional treatment. Severe painful hematuria and pro-
tracted bladder catheterization, because of the required
systemic opioid analgesia and prolonged immobilization
with increasing risk of developing other related comorbid-
ities, are relevant causes of physical and psychological
discomfort for patients. In this study, both the parameters of
pelvic pain and time to catheter removal have been pro-
spectively evaluated and it was documented that all FG-
treated patients found relief from the procedure with
disappearance of pelvic pain and discontinuation of anal-
gesic agents at a median of 24 hours in each case, whereas
the Foley catheter was removed in 93% at a median of 5 days.
Several studies of the treatment of severe HC in HSCT
have reported responses ranging from 50% to 100% [5].
However, most of these studies are retrospective and refer to
at least 19 different types of therapy [15]. Furthermore, in
the majority of these studies, the response criteria
are not well deﬁned. To date, no prospective study
strictly addressing the treatment of the refractory post-
transplantation HC in adults has been published. Over an
observation period of 7 years, we evaluated feasibility and
efﬁcacy of intravesical FG as a single treatment approach for
severe HC in a consecutive series of patients undergoing
allogeneic HSCT for hematological malignancies. Of 322mplete remission by median time from HC onset to FG therapy (B). CI indicates
Figure 5. Matched-pair analysis. Five-year probability of overall survival for
the 35 patients with hemorrhagic cystitis treated with ﬁbrin glue (FG-HC)
versus 35 patients without hemorrhagic cystitis (No HC).
M.C. Tirindelli et al. / Biol Blood Marrow Transplant 20 (2014) 1612e16171616allogeneic transplant recipients, 45 developed HC of grade
2 and FG therapy was feasible in 35 (78%). In terms of ef-
ﬁcacy, FG therapy allowed 29 patients to achieve CRwith a CI
of 83%  7% at median of 14 days. Although not statistically
signiﬁcant, a higher response was observed in patients
treated early with FG, suggesting that starting therapy
quickly is beneﬁcial.
Many studies suggest that BKV reactivation contributes to
the pathogenesis of late-onset HC [44]. Therefore, the anti-
viral agent cidofovir given intravenously at standard or low
dose, or locally by bladder instillation, has been proposed in
the treatment of HC, with positive results in a proportion of
patients ranging from 60% to 84% [12,27,45].
However, all these studies, frequently referred to pediat-
ric series, are retrospective, include a limited number of
patients, and lack well-deﬁned criteria of clinical and viral
response. Moreover, HC remission can be achieved either by
patients treated or untreated with cidofovir and receiving
only supportive care; furthermore, the self-limiting nature of
late-onset HC has been also reported [12,46].
The present study includes only adult patients with grade
2 HC, for whom criteria of response to FG therapywerewell
deﬁned. Themedian time to clinical response of 24 hours and
5 days for pelvic pain disappearance and catheter removal,
respectively, together with a median time to CR of 14 days,
strongly support the effective role of FG therapy in improving
HC complications. BKV positivity remained substantially
unchanged in patients achieving CR and no correlation was
observed between cidofovir treatment and response. HC is
frequently correlated with a reduced probability of survival
after allogeneic HSCT [7,8]. The matched-pair analysis
showed no statistically signiﬁcant difference in terms of
survival between patients with HCwhowere treatedwith FG
and patients who did not have HC. The results of this study
suggest that the endoscopic application of FG should be
considered a feasible, safe, noninvasive, easily repeatable,
low time-consuming, and inexpensive procedure for the
management of severe HC developing in frail and highly
immunocompromised patients. However, endoscopic FG
therapy needs the compliance of urologists and the avail-
ability of the Vivostat system, with technical features that
were proven, in our hands, to be suitable for its intended use.
FG for treating HC should be investigated on a large, pro-
spective, multicenter trial.ACKNOWLEDGMENTS
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